论文部分内容阅读
目的：观察脂必妥片的调脂疗效及其安全性。方法：采用随机、双盲对照观察的方法，分为脂必妥组和对照组。脂必妥组１５例（男性４例，女性１１例；年龄６０±ｓ５ａ）。对照组１５例（男性１０例，女性５例；年龄６３±３ａ）。分别给予脂必妥或淀粉片３粒，ｐｏ，ｔｉｄ，共８ｗｋ。结果：脂必妥组血胆固醇（ＴＣ）、三酰甘油（ＴＧ）和高密度脂蛋白胆固醇（ＨＤＬ－ｃｈ）的总有效率分别为８３％，８６％，１００％。症状的总有效率为１００％，并见有体重减轻。上述结果与对照组比均有显著差异。其中，ＴＧ，ＨＤＬ－ｃｈ和低密度脂蛋白胆固醇在治疗４ｗｋ时已有改善（Ｐ＜０．０５，或０．０１）。治疗期间无不良反应。结论：脂必妥为安全有效的调脂药物。
Objective: To observe the lipid-lowering efficacy and safety of Zhibituo tablets. Methods: A randomized, double-blind controlled observation method was divided into the group and the control group. Lipid group of 15 patients (4 males and 11 females; age 60 ± s5a). Control group of 15 patients (10 males and 5 females; age 63 ± 3a). Respectively to give liposide or starch tablets 3, po, tid, a total of 8wk. Results: The total effective rates of TC, TG and HDL-C in the lipidostat group were 83%, 86% and 100%, respectively. The total effective rate of symptoms was 100%, and see a weight loss. The above results compared with the control group were significantly different. Among them, TG, HDL-ch and low density lipoprotein cholesterol had improved at 4wk (P <0.05, or 0.01). No adverse reactions during treatment. Conclusion: Lipid is a safe and effective lipid-lowering drug.